Cell and Gene Commercialization
-
2024 Regulatory Outlook With FDA's Drs. Peter Marks And Nicole Verdun
1/25/2024
Explore the evolving regulatory landscape for cell and gene therapies in 2024 including the increasing speed availability of cell and gene therapies by enabling manufacturing processes and standards development.
-
Shaping A Digitally Enabled Commercialization Road Map For Your Cell/Gene Therapy Company
1/25/2024
For cell and gene therapy companies, it is critical for commercial, marketing, and digital leaders to understand key business decisions that shape the digital backbone of your commercialization road map.
-
Paving The Way For India’s First Domestic CAR-T Approval
1/22/2024
India recently saw the approval of its first domestic CAR-T cell therapy, NexCAR19. This not only marks a significant achievement for the country, but for the CGT industry as a whole. To learn more about this journey to approval, I met with ImmunoACT, the pioneer behind NexCAR19.
-
Transforming CGT With A Synergistic Partnership
1/18/2024
Understand the strategic advantages of a new collaboration and discover how two companies' unified vision promises to elevate CGT to new heights, one empowered patient at a time.
-
The Future Of mRNA For Cancer Treatment
1/9/2024
As additional mRNA-based cancer immunotherapies vaccines enter clinical development, operational and supply chain challenges must be addressed to reduce turnaround times and COGS.
-
Cell & Gene Therapies: How Can Our Knowledge Of 2023 Inform Our Predictions For 2024?
1/8/2024
2024 promises a potential turnaround and blue skies for cell and gene therapies. Let’s explore each modality’s prospects: oligos and mRNA, cell therapies, and viral gene therapies.
-
A Look At siRNA & Market Trends
1/3/2024
Small interfering RNA (siRNA) is a class of molecules that play a crucial role in the regulation of gene expression. This article shares how siRNA functions as well as new market research for the field.
-
How Well-Supported Is The Current Technology Vendor Space?
1/2/2024
Take a look at the current cell and gene technological landscape, along with how well industry needs are being met and where there is room for improvement.
-
How Automation Improves Safety And Efficacy Of Source Material Collection
12/13/2023
Implementing more automated workflows in cell therapy manufacturing can serve to minimize open processes and manual touchpoints, increasing reproducibility and improving traceability.
-
Preparing Your CAR-T Therapy For Phase 2 Trials
12/6/2023
AffyImmune CEO, Matt Britz, talks about what’s next for the company as it prepares its lead CAR-T candidate for Phase 2 trials — from clinical strategy to selecting a CDMO and the headache of tech transfers.